Is this opioid analgesic tolerance?

Journal of Pain and Symptom Management

Volumn 10, Issue 7, 1995, Pages 573-577

  Fainsinger, Robin L ^a   Bruera, Eduardo ^a  

^a Edmonton General Hospital   (Canada)

Author keywords

analgesic; opioid; Tolerance

Indexed keywords

DIAMORPHINE; FENTANYL; HALOPERIDOL; HYDROMORPHONE; METHADONE; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT;

AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CASE REPORT; DELIRIUM; DRUG TOLERANCE; HALLUCINATION; HUMAN; MALE; METHADONE TREATMENT; MULTIPLE MYELOMA; MYOCLONUS; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0028857831     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/0885-3924(95)00088-G     Document Type: Article

References (22)

1. Clinical tolerance to opioids
2. Drug addiction and drug abuse
3. Opioid analgesic therapy
4. Controversies in the long-term management of analgesic therapy in patients with advanced cancer
5. Cancer pain management
6. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain
7. “Minimental state:” a practical method for grading the cognitive state of patients for the clinician
8. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure
9. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine
10. Pain syndromes and their treatment
11. Paradoxical Pain
12. Paradoxical pain
13. Individual variability in response to different opioids report of 5 cases
14. Evaluation of analgesics in patients with cancer pain
15. The treatment of cancer pain
16. Methadone in the management of cancer pain: a review
17. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain
18. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine resistant pain
19. The NMDA receptor antagonists, LY 274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-l-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids
20. Terminal restlessness: its management and role of midazolam
21. A perspective on the management of delirium in the terminally ill